In vitro uses of human pluripotent stem cell-derived cardiomyocytes

J Cardiovasc Transl Res. 2012 Oct;5(5):581-92. doi: 10.1007/s12265-012-9376-5. Epub 2012 May 26.


Functional cardiomyocytes can be efficiently derived from human pluripotent stem cells (hPSCs), which collectively include embryonic and induced pluripotent stem cells. This cellular platform presents exciting new opportunities for development of pharmacologically relevant in vitro screens to detect cardiotoxicity, validate novel drug candidates in preclinical trials and understand complex congenital cardiovascular disorders, to advance current clinical therapies. Here, we discuss the progress and impediments the field has faced in using hPSC-derived cardiomyocytes for these in vitro applications, and highlight that rigorous protocol optimisation and standardisation, scalability and automation are remaining obstacles for the generation of pure, mature and clinically relevant hPSC cardiomyocytes.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Biomarkers / metabolism
  • Cell Culture Techniques
  • Cell Differentiation
  • Cell Lineage
  • Cell Proliferation
  • Cell Separation
  • Cells, Cultured
  • Embryonic Stem Cells* / drug effects
  • Embryonic Stem Cells* / metabolism
  • Embryonic Stem Cells* / pathology
  • Gene Expression Regulation, Developmental
  • Genotype
  • Heart Diseases / genetics
  • Heart Diseases / metabolism
  • Heart Diseases / pathology
  • Humans
  • Induced Pluripotent Stem Cells* / drug effects
  • Induced Pluripotent Stem Cells* / metabolism
  • Induced Pluripotent Stem Cells* / pathology
  • Morphogenesis
  • Myocytes, Cardiac* / drug effects
  • Myocytes, Cardiac* / metabolism
  • Myocytes, Cardiac* / pathology
  • Phenotype
  • Toxicity Tests


  • Biomarkers